Drug Trial Radar · NCT04176848
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Aug 10, 2020
Primary completion
Sep 15, 2022
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- AstraZeneca; University Health Network, Toronto
- First posted
- Nov 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.
Conditions
- Breast Cancer
Interventions
CFI-400945Drug
CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
DurvalumabDrug
Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: 24 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.